Hauser RA - Search Results

1

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators. LeWitt PA, et al. Among authors: hauser ra. Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Lancet Neurol. 2019. PMID: 30663606 Clinical Trial.

2

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Hauser RA, et al. Neurology. 2003 Aug 12;61(3):297-303. doi: 10.1212/01.wnl.0000081227.84197.0b. Neurology. 2003. PMID: 12913187 Clinical Trial.

3

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Truong D, et al. Among authors: hauser ra. Mov Disord. 2005 Jul;20(7):783-91. doi: 10.1002/mds.20403. Mov Disord. 2005. PMID: 15736159 Clinical Trial.

4

Ropinirole therapy for Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA. Pahwa R, et al. Among authors: hauser ra. Expert Rev Neurother. 2004 Jul;4(4):581-8. doi: 10.1586/14737175.4.4.581. Expert Rev Neurother. 2004. PMID: 15853577 Review.

5

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Zesiewicz TA, et al. Among authors: hauser ra. Mov Disord. 2005 Sep;20(9):1205-9. doi: 10.1002/mds.20563. Mov Disord. 2005. PMID: 15954135

6

Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia.

Graff-Radford J, Foote KD, Rodriguez RL, Fernandez HH, Hauser RA, Sudhyadhom A, Rosado CA, Sanchez JC, Okun MS. Graff-Radford J, et al. Among authors: hauser ra. Arch Neurol. 2006 Aug;63(8):1181-4. doi: 10.1001/archneur.63.8.1181. Arch Neurol. 2006. PMID: 16908749

7

Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.

Hauser RA. Hauser RA. Geriatrics. 2006 Sep;61(9):14-20. Geriatrics. 2006. PMID: 16989543 Review.

8

Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease.

Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK. Hauser RA, et al. Clin Neuropharmacol. 2006 Nov-Dec;29(6):322-30. doi: 10.1097/01.WNF.0000229546.81245.7F. Clin Neuropharmacol. 2006. PMID: 17095895

9

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. Zesiewicz TA, et al. Among authors: hauser ra. Mov Disord. 2007 Jan 15;22(2):279-82. doi: 10.1002/mds.21282. Mov Disord. 2007. PMID: 17149715 Clinical Trial.

10

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.

Hauser RA, McDermott MP, Messing S. Hauser RA, et al. Arch Neurol. 2006 Dec;63(12):1756-60. doi: 10.1001/archneur.63.12.1756. Arch Neurol. 2006. PMID: 17172616 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page